ABSTRACT
Chronic obstructive pulmonary disease (COPD) can be accompanied by compensatory secondary erythrocytosis. However, the exact prevalence of secondary erythrocytosis in COPD is unknown. Although diagnostic criteria for polycythemia vera versus secondary erythrocytosis are mutually exclusive, we describe here the coexistence of polycythemia vera and COPD in the same patient.
Subject(s)
Lung Diseases, Obstructive/complications , Polycythemia/complications , Aged , Humans , Male , Polycythemia Vera/complications , Polycythemia Vera/epidemiology , PrevalenceABSTRACT
The treatment of the diabetic foot is a common and sometimes difficult problem. The treatment of the characteristic lesions of the diabetic foot involves many forms of therapy: these include contact dressings and topical treatments. The different therapies that have been applied do not often give satisfactory results. Therefore, for this purpose, we have studied the effect of biostimulation of wound-healing by utilising the CO2 laser together with the action of the KTP laser on 25 patients (11 females and 14 males), all suffering from diabetes mellitus with polyneuropathic ulcers of the foot. Low out-put laser irradiation may stimulate granulation tissue and collagen production in fibroblasts. Many studies observed a regeneration of microcirculation in the ulcer and a regeneration of lymphatic circulation. The laser irradiation method produces a sterilizing effect from bacteria that over-infect the diabetic ulcer too. Each patient underwent a surgical treatment of the edges of the ulcers with CO2 and KTP laser (wavelength 532 nm) focused, and a combined phototherapy (CO2 laser and afterwards KTP laser, defocused). The irradiation was carried out through laser beam (by optic fiber for KTP) manually directed, until all of the ulcer surface became irradiated. On the skin around the ulcer, an omental derived cream (fractionated porcine omental lipid extracts) was daily applied, independently from the laser treatment, to evaluate the angiogenic effect of this substance.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Diabetic Foot , Administration, Topical , Adult , Aged , Carbon Dioxide , Combined Modality Therapy , Diabetic Foot/drug therapy , Diabetic Foot/prevention & control , Diabetic Foot/surgery , Diabetic Neuropathies/drug therapy , Diabetic Neuropathies/prevention & control , Diabetic Neuropathies/surgery , Female , Humans , Laser Therapy , Lipids/administration & dosage , Lipids/analysis , Lipids/therapeutic use , Male , Middle Aged , Omentum , Tissue Extracts , Wound HealingABSTRACT
The aim of this study was to evaluate the insulin (IRI) response to different stimuli and insulin sensitivity in Type 2 diabetic patients responsive to oral hypoglycaemic agents (OHA) and in Type 2 diabetic patients with secondary failure of OHA (SF), all patients being of normal body weight (relative body weight less than 120%), and the possible role of cyclic AMP in the reduced IRI release. SF patients, without islet cell antibodies (ICA), with hyperglycaemia lasting more than 3 months, underwent tests with i.v. tolbutamide (n = 21), i.v. glucose (n = 14), i.v. glucagon (n = 19), i.v. arginine infusion (n = 18); the arginine infusion was repeated in 12 patients during administration of aminophylline, an inhibitor of phosphodiesterase. The same tests were performed in groups of 8 to 15 OHA patients and in groups of 6 to 17 healthy subjects. During all the tests, blood glucose levels were higher in SF patients, than in OHA patients and in healthy subjects. Both SF patients and OHA patients had no IRI response to glucose; SF patients, in contrast to OHA patients, had a reduced IRI response to tolbutamide and to glucagon. The IRI response to arginine was not different in OHA, in SF patients and in healthy controls, but was significantly enhanced by aminophylline only in healthy controls. Insulin infusions (1.66 mU/Kg/min for 90 min) were performed in OHA patients and in SF patients at blood glucose levels of 150 and of 250 mg/dl: during the last 60 min, the amount of glucose metabolized (M), and the insulin sensitivity (M/I) index were greater in OHA than in SF patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Cyclic AMP/physiology , Diabetes Mellitus, Type 2/drug therapy , Glyburide/therapeutic use , Insulin/therapeutic use , Aminophylline/pharmacology , Aminophylline/therapeutic use , Arginine/pharmacology , Blood Glucose/metabolism , Body Weight , Diabetes Mellitus, Type 2/blood , Eating , Female , Glycated Hemoglobin/analysis , Humans , Insulin/blood , Insulin Infusion Systems , Male , Middle Aged , Thinness , Tolbutamide/pharmacologyABSTRACT
It has been shown that human calcitonin (hCT) is absorbed through the nasal mucosa when administered together with promoters like sodium glycocholate (SGC) or dihydrofusinate. The aim of this study was to compare the clinical and metabolic effect of intranasal (in) and intramuscular (im) hCT in patients with osteoporosis or with Paget's disease of bones. Fifteen women with postmenopausal or with senile osteoporosis entered a randomized six months trial with in hCT (plus SGC) or with im hCT 100 U on alternate days. Six women in each group were treated for 2 months, and only four women in each group continued treatment for an additional 4 months period. In hCT, but not im hCT, reduced subjective pain, while urinary cAMP increased to a similar extent in the 2 groups. Other metabolic indexes and bone mineral content (BMC) were unchanged, no new fractures took place, and side effects were fewer with in than with im hCT. To confirm the analgesic effect of in hCT, twelve patients with Paget's disease of bone were randomly treated for 20 days with in or im hCT 100 U/day: during the short period of treatment, pain was reduced by in, not by im hCT, and urinary cAMP excretion similarly increased in the two groups of patients.
Subject(s)
Calcitonin/therapeutic use , Osteitis Deformans/drug therapy , Osteoporosis/drug therapy , Administration, Intranasal , Aged , Bone Density/drug effects , Calcitonin/administration & dosage , Calcitonin/pharmacology , Cyclic AMP/urine , Female , Humans , Injections, Intramuscular , Middle Aged , Osteitis Deformans/metabolism , Osteoporosis/metabolism , Osteoporosis, Postmenopausal/drug therapy , Osteoporosis, Postmenopausal/metabolism , Pain/drug therapy , Pilot ProjectsABSTRACT
Occurrence of hypoglycemia during a prolonged fasting, accompanied by inappropriately high serum insulin levels, is considered a reliable index of the presence of insulinoma. Previous in vitro studies on insulin receptors, and in vivo hyperinsulinemic clamps have shown that patients with insulinoma are insulin resistant. In the present study 10 patients with insulinoma, 6 patients with nontumoral (also called functional or reactive hypoglycemia) hypoglycemia and 6 normal subjects were fasted for 24 h and their blood glucose levels were maintained constant by means of a programmed glucose infusion (isoglycemic glucose clamp) delivered by an artificial pancreas (Biostator). Blood glucose levels were monitored in continum, glucose infused (M) and glucose clearance (MCR) were evaluated at hourly intervals, and serum insulin (IRI) levels were evaluated every 6 h. Blood glucose levels were higher in controls than in patients with insulinoma and in patients with non tumoral hypoglycemia; M, MCR and IRI were progressively higher in controls, in patients with nontumoral hypoglycemia and in patients with insulinoma. The M/I index (M divided by IRI levels, an index of insulin sensitivity) was lower in patients with insulinoma than in other subjects and patients, indicating the existence of insulin resistance. These data indicate that: i) patients with insulinoma require large amounts of glucose to remain isoglycemic during a prolonged fast; ii) insulin resistance is a common feature of insulinoma and can be shown even under near physiologic conditions such as a 24-h fasting. The present study does not clarify whether insulin resistance occurs at the hepatic level or at other, peripheral levels.
Subject(s)
Glucose Clamp Technique , Hypoglycemia/diagnosis , Adolescent , Adult , Aged , Blood Glucose/analysis , Blood Glucose/pharmacokinetics , Humans , Hypoglycemia/pathology , Hypoglycemia/physiopathology , Insulin/blood , Insulin Resistance/physiology , Insulinoma/complications , Insulinoma/diagnosis , Insulinoma/physiopathology , Metabolic Clearance Rate , Middle AgedABSTRACT
Intranasal glucagon can raise blood glucose levels in healthy subjects. The aims of this study were to 1) compare the hyperglycemic effect of intranasal and intramuscular glucagon in healthy subjects and type I (insulin-dependent) diabetes patients during euglycemic conditions and 2) test the efficacy of intranasal and intramuscular glucagon in counteracting hypoglycemic episodes in insulin-treated diabetic patients. Intranasal glucagon raised blood glucose levels in both healthy subjects and type I diabetic patients, the effect of intramuscular glucagon being similar for the first 30 min and higher thereafter. Intranasal glucagon was also quicker acting than oral glucose in healthy subjects. Intranasal glucagon raised blood glucose levels in patients with hypoglycemic episodes, although less effectively than intramuscular glucagon. These data indicate intranasal glucagon as a possible emergency remedy for self-medication in insulin-treated patients prone to hypoglycemic episodes.
Subject(s)
Diabetes Mellitus, Type 1/blood , Glucagon/administration & dosage , Hypoglycemia/drug therapy , Administration, Intranasal , Adult , Diabetes Mellitus, Type 1/complications , Glucagon/pharmacology , Glucagon/therapeutic use , Humans , Hypoglycemia/etiology , Insulin/blood , Kinetics , Middle Aged , Random Allocation , Reference ValuesABSTRACT
The systemic availability of glucagon and human calcitonin given intranasally to healthy volunteers as spray solutions or powders has been examined. Glucagon was absorbed only when surfactants were used, and 9-lauryl ether (as a spray) and sodium glycocholate (as spray or powder) were equally active. Calcitonin was poorly absorbed when given alone but the surfactants dihydrofusinate (as spray or powder) and glycocholate (as a spray) were equally active in promoting absorption. Thus, enhancers are required to obtain significant nasal absorption of glucagon and calcitonin and powders and spray solutions did not differ in terms of systemic availability.
Subject(s)
Calcitonin/pharmacokinetics , Glucagon/pharmacokinetics , Administration, Intranasal , Adult , Calcitonin/administration & dosage , Drug Compounding , Glucagon/administration & dosage , Humans , Powders , Random Allocation , Solutions , Surface-Active Agents/adverse effectsABSTRACT
Intranasal insulin is effective in raising serum insulin (IRI) levels and lowering blood glucose levels in normal subjects and in diabetics, but its bioavailability is low. Our aim was to improve the bioavailability of intranasally administered insulin in normal subjects as a prerequisite to extended clinical trials. Solutions of regular porcine and human insulin, 40 U/ml, with sodium glycocholate 1 % w/v as a surfactant, administered in drops (0.9 U/Kg b.w.), were equally effective in terms of bioavailability and of hypoglycaemic activity. Spray solutions (0.5 U/Kg b.w.) of human insulin, 100 U/ml, were more effective than drops, and of the two surfactants employed, sodium glycocholate 4 % w/v was significantly more effective than 9-lauryl-ether and more effective than other formulations used here or described by other authors. Although being subject to further improvement, the formulation of human insulin 100 U/ml plus sodium glycocholate 4 % w/v delivered as a spray solution described in this study appears to be worthy of clinical trials in diabetic patients.
Subject(s)
Glycocholic Acid , Insulin/pharmacokinetics , Administration, Intranasal , Biological Availability , Blood Glucose/metabolism , Double-Blind Method , Humans , Insulin/administration & dosage , Insulin/bloodABSTRACT
Ceruletide is a synthetic decapeptide closely resembling the 8-carboxy-terminal peptide of cholecystokinin (CCK-8) with which it shares several biological properties. In a double-blind study versus placebo, we evaluated the effects of ceruletide on self-rated hunger and food intake at lunch time, as well as on body weight in 14 obese women hospitalized for weight reduction and on a restricted diet. During two 6-day courses of treatment with ceruletide or placebo, ceruletide 0.3 microgram/kg b.wt. or an equivalent volume of its diluent were injected IM at 11.30 a.m., i.e., 30 min before lunch. Feelings of hunger were quantitated, using a visual analogue self-rating scale, prior to the injection of ceruletide or placebo and 30 min thereafter, i.e., just prior to the start of meal ingestion, as well as 2 hr after the start of the meal. Duration and caloric content of food ingested at lunch, as well as morning body weight, were recorded daily. Ceruletide, compared to placebo, did not significantly influence any of the above variables. However, in the first three experimental days, the increase in self-rated hunger from values before the injection to 30 min thereafter was less marked, though not significantly so (0.05 less than p less than 0.1), with ceruletide than with placebo. Thus, it appears that ceruletide, under the experimental conditions of the present study, was not effective in enhancing the patients' motivation to lose weight and to further restrict their food intake at lunch time.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Appetite Depressants , Ceruletide/pharmacology , Obesity/drug therapy , Adolescent , Adult , Body Weight/drug effects , Clinical Trials as Topic , Diet, Reducing , Double-Blind Method , Female , Humans , Hunger/drug effects , Middle Aged , Obesity/diet therapy , Obesity/psychology , Random AllocationABSTRACT
Glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured by constant inulin and PAH infusion during euglycemia and intravenous dextrose-induced moderate hyperglycemia in seven insulin-dependent diabetics with persistently elevated GFR, seven diabetics with normal GFR, and in six normal control subjects. In euglycemia, RPF was higher and calculated renal vascular resistance (RVR) lower in the hyperfiltering than the normofiltering group (P less than 0.05 for both variables), but filtration fraction (FF) was similar in all groups. During hyperglycemia, mean GFR rose significantly from 157 +/- 20 to 174 +/- 30 ml/min/1.73 m2 (11.9%; P less than 0.05) in the hyperfiltering group only. There was no statistically significant change in mean GFR in the normofiltering diabetic (116 +/- 6 vs. 114 +/- 13 ml/min/1.73 m2) and the normal control groups (117 +/- 15 vs. 113 +/- 14 ml/min/1.73 m2). RPF and FF rose by 5.8% and 9.2%, respectively, in the hyperfiltering group only, with no change in the normofiltering or normal control groups. No change in RVR was found in any group. Total tubular sodium reabsorption was higher during euglycemia in the hyperfiltering diabetics (P less than 0.01), and rose significantly during hyperglycemia (P less than 0.05) in this group only. Overnight euglycemia did not remove the increased glomerular filtration and flow of hyperfiltering diabetics. Hyperglycemia further accentuated hyperfiltration by elevating renal plasma flow and filtration fraction.
Subject(s)
Blood Glucose/metabolism , Diabetic Nephropathies/physiopathology , Kidney Glomerulus/physiopathology , Adult , Blood Pressure , Diabetic Nephropathies/blood , Glomerular Filtration Rate , Humans , Hyperglycemia/physiopathology , Insulin/blood , Male , Renal Circulation , Sodium/metabolism , Vascular ResistanceABSTRACT
In three hyperthyroid women aged more than 60 years serum TSH levels, inhibited as usual before treatment, rose and remained elevated for more than one year while on treatment with methimazole and l-thyroxine, in spite of serum T3 and T4 levels within the normal range. In two hypothyroid women aged more than 60 years, serum TSH levels, raised under basal conditions, failed to be suppressed by a one-year treatment with l-thyroxine. Repeated attempts to increase serum T3 and T4 concentrations by giving additional doses of l-thyroxine or by tapering methimazole dosage, led to clinical signs of hyperthyroidism, not accompanied by a significant reduction of serum TSH levels. These data indicate the possibility of an inappropriate TSH release in some elderly people.
Subject(s)
Thyrotropin/metabolism , Aged , Female , Humans , Hyperthyroidism/blood , Hyperthyroidism/drug therapy , Hypothyroidism/blood , Hypothyroidism/drug therapy , Methimazole/therapeutic use , Middle Aged , Thyrotropin/blood , Thyroxine/blood , Thyroxine/therapeutic use , Triiodothyronine/bloodABSTRACT
Intranasal administration of glucagon, 1 mg, plus sodium glycocholate 15 mg as a surfactant, raised blood glucose levels and plasma levels of immunoreactive glucagon (IRG) and immunoreactive insulin (IRI). Spray solutions were more effective than drops, and neither the surfactant alone nor glucagon alone had any effect. Blood glucose levels were similarly affected by intravenous glucagon, while intramuscular glucagon was slightly more effective. The highest IRG concentrations were reached after intravenous administration, while intramuscular injection of glucagon was accompanied by the highest IRI release. These data indicate that intranasal administration of glucagon exerts metabolic effects similar to intramuscular and intravenous administrations. Further studies are needed to improve bioavailability and efficacy of intranasally administered glucagon.
Subject(s)
Blood Glucose/metabolism , Glucagon/administration & dosage , Insulin/blood , Administration, Intranasal , Adult , Female , Glucagon/blood , Glucagon/pharmacology , Glycocholic Acid , Humans , Injections, Intramuscular , Injections, Intravenous , Male , Pharmaceutical Vehicles , Random Allocation , Surface-Active AgentsSubject(s)
Calcitonin/administration & dosage , Gastrointestinal Hormones/administration & dosage , Hypothalamic Hormones/administration & dosage , Insulin/administration & dosage , Pituitary Hormones/administration & dosage , Thyroid Hormones/administration & dosage , Administration, Intranasal , Administration, Oral , Animals , Humans , Injections, Intra-Arterial , Rats , RectumABSTRACT
Indirect evidence suggests that sulfonylureas, in addition to stimulating insulin release, exert additional effects at extrapancreatic levels which are of value in the management of type 2 diabetes. In order to characterize in vivo some of these effects, insulin sensitivity was studied in 9 type 1 diabetics with no residual insulin secretory activity, during treatment with chlorpropamide (250 mg b.i.d. for 8 days) and with glipizide (5 mg t.i.d. for 8 days). Employing the glucose clamp technique with the aid of an artificial pancreas (Biostator), glucose disposal during insulin infusion (0.1 U/kg in 60 min) was calculated by the amount of glucose required to keep the blood glucose at preinfusion levels. Chlorpropamide and glipizide administration was accompanied by a significant increase of the amount of glucose required to clamp blood glucose levels, while serum (free) insulin levels were superimposable during the different clamping studies. In the absence of endogenous insulin release, these data strongly suggest that the two sulfonylureas employed enhance in vivo the peripheral sensitivity to insulin. Further studies are required to indicate a preferential site of action (liver, muscle, adipose tissue) of sulfonylureas.
Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Insulin/therapeutic use , Sulfonylurea Compounds/therapeutic use , Adolescent , Adult , Chlorpropamide/therapeutic use , Drug Interactions , Female , Glipizide/therapeutic use , Humans , Insulin/blood , Male , Tolbutamide/therapeutic useABSTRACT
Using the artificial pancreas, blood glucose levels were maintained at 80 mg/dl in nine hypoglycemic patients (four with histologically proven insulinomas and five with nontumoral hypoglycemia) and in four normal subjects during a 24-h fast. The amount of glucose used, serum insulin levels, and glucose clearance were higher in patients with nontumoral hypoglycemia than in normal subjects and highest in the patients with an insulinoma. Surgical or pharmacological treatment resulted in normalization of all parameters. In contrast to the 72-h fast, the 24-h glucose clamp technique allowed the study of hypoglycemic patients without inducing hazardous hypoglycemia.